AbCellera takes ownership of anti-OX40L antibody from EQRx for autoimmune therapy

AbCellera Biologics Inc.

Acquired rights to an antibody drug candidate targeting Ox40 ligand from EQRx collaboration.
Candidate is being developed for atopic dermatitis and other autoimmune/inflammatory indications.
AbCellera is advancing the candidate into IND-enabling studies; updates to follow.
No financial terms of the asset transfer were disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.